{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Advancing Predictive Biomarkers for Colon Cancer Treatment
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Explain current limitations of precision oncology regarding predictive biomarkers for colon cancer treatment.
- Summarize the results of the study and their implications for clinical practice and future research.
Learning Outcomes
By the conclusion of this activity, a majority of the participants will demonstrate knowledge of research that identified and validated a 10-gene biomarker that could potentially predict which patients with stage II or III colon cancer would benefit from adjuvant chemotherapy by achieving a passing score on the posttest.Disclosures
All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
- NM - BON 1.0 CH
- SC - BON 1.0 CH
- WV - BOERN 1.0 CH
Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT1124
Published: November 2024
Expires: 12/4/2026
Sources:
Oncology Times
Required Passing Score: 4/5 (80%)